Trial Profile
A 36-week, Randomized, Double-blind, Multi-center, Parallel Group, Active Controlled Study to Evaluate the Efficacy, Safety and Tolerability of LCZ696 Compared to Valsartan in Patients With Chronic Heart Failure and Preserved Left-ventricular Ejection Fraction
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Jul 2023
Price :
$35
*
At a glance
- Drugs Sacubitril/valsartan (Primary) ; Valsartan
- Indications Chronic heart failure
- Focus Registrational; Therapeutic Use
- Acronyms PARAMOUNT; PARAMOUNT-HF
- Sponsors Novartis
- 01 Jun 2023 Results assessing whether treating patients with heart failure with preserved ejection fraction with sacubitril/valsartan would significantly improve GLS and GCS compared with valsartan alone, published in the Journal of Cardiac Failure
- 15 Dec 2020 According to a Novartis media release, based on the data from PARAGON-HF, PARAMOUNT and PARADIGM-HF studies, the US Food and Drug Administration (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC) voted 12 to 1 that the data presented support the use of Entresto (sacubitril/valsartan) in treatment of patients with heart failure with preserved ejection fraction (HFpEF).
- 01 Apr 2014 Results published in the European Journal of Heart Failure.